{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03943290: Phase 2 Interventional Terminated Facioscapulohumeral Muscular Dystrophy
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00284804: Phase 2 Interventional Completed Hodgkin's Disease
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04171986: Not Applicable Interventional Unknown status Small Cell Lung Cancer
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03578809: Phase 2 Interventional Completed ST Elevation Myocardial Infarction
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04130854: Phase 2 Interventional Active, not recruiting Locally Advanced Rectal Adenocarcinoma
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:vandortuzumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04235868: Phase 1 Interventional Unknown status Mesenchymal Stem Cell-derived Bioactivator for Treating Chronic Wounds
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03941093: Phase 3 Interventional Completed Pancreatic Cancer Non-resectable
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03030287: Phase 1 Interventional Completed Cancer Ovaries
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
